Publications (original articles or review articles) published in 2024 from OUS - Dept. of Microbiology, Dudman - Clinical Virology Research Group
10 publications found
Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections
NPJ Vaccines, 9 (1), 185
DOI 10.1038/s41541-024-00972-3, PubMed 39384763
Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial
Lancet Glob Health, 12 (8), e1300-e1311
DOI 10.1016/S2214-109X(24)00193-1, PubMed 39030061
Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients
J Intern Med, 296 (1), 80-92
DOI 10.1111/joim.13783, PubMed 38539241
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Viruses, 16 (6)
DOI 10.3390/v16060858, PubMed 38932151
Clinical Evaluation of the VirClia IgM/IgG Chemiluminescence Tests for the Diagnosis of Tick-Borne Encephalitis in an Endemic Part of Norway
Viruses, 16 (9)
DOI 10.3390/v16091505, PubMed 39339981
Modeling the relative influence of socio-demographic variables on post-acute COVID-19 quality of life
medRxiv
DOI 10.1101/2024.02.21.24303099, PubMed 39040190
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203
Epidemiological and clinical insights into the enterovirus D68 upsurge in Europe 2021/22 and the emergence of novel B3-derived lineages, ENPEN multicentre study
J Infect Dis (in press)
DOI 10.1093/infdis/jiae154, PubMed 38547499
Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies
Harm Reduct J, 21 (1), 120
DOI 10.1186/s12954-024-01023-9, PubMed 38890611
Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial
Lancet Glob Health, 12 (8), e1288-e1299
DOI 10.1016/S2214-109X(24)00192-X, PubMed 39030060